fbpx
Wikipedia

Peginterferon alfa-2a

May 07, 2024

Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B.[2] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%.[2][3] For hepatitis B it may be used alone.[4] It is given by injection under the skin.[2]

Peginterferon alfa-2a
Clinical data
Trade namesPegasys, others
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa605029
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: WARNING[1]Rx-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
  • 198153-51-4 Y
  • alfa-2b: 215647-85-1 Y
DrugBank
  • DB00008 Y
ChemSpider
  • none
UNII
  • Q46947ZFE7K
  • alfa-2b: G8RGG88B68 Y
KEGG
  • D02748 Y
ChEMBL
  • ChEMBL1201560 N
Chemical and physical data
FormulaC860H1353N227O255S9
Molar mass19241.16 g·mol−1
 NY (what is this?)  (verify)

Side effects are common.[5] They may include headache, feeling tired, depression, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever.[2] Severe side effects may include psychosis, autoimmune disorders, blood clots, or infections.[2] Use with ribavirin is not recommended during pregnancy.[2] Pegylated interferon alfa-2a is in the alpha interferon family of medications.[2] It is pegylated to protect the molecule from breakdown.[5]

Pegylated interferon alfa-2a was approved for medical use in the United States in 2002.[2] It is on the World Health Organization's List of Essential Medicines.[6]

Medical uses edit

This drug is approved around the world for the treatment of chronic hepatitis C (including people with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B. It is also used in the treatment of certain T-cell lymphomas, particularly mycosis fungoides.[citation needed]

Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections. Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system.[7]

Host genetic factors edit

For genotype 1 hepatitis C treated with pegylated interferon alfa-2a or pegylated interferon alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature,[8] showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Another report in Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.[9]

Manufacturing edit

It is pegylated with a branched 40 kg/mol PEG chain.[10]

Society and culture edit

Availability edit

Peginterferon alfa-2a is manufactured under the brand name Pegasys. In 2021, Roche Pharmaceuticals sold the worldwide rights of Pegasys (excluding China and Japan) to zr pharma& GmbH (pharma&).[11][12][13][14][15] In May 2022, Roche Australia transferred the sales and marketing of Pegasys to Echo Therapeutics Pty Ltd.[16]

Research edit

A Cochrane Review sought to determine whether interferon alfa-2a could be used as a treatment for individuals with neovascular age-related macular degeneration. They found no evidence of improved visual acuity with potential harm.[17]

References edit

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  2. ^ a b c d e f g h "Peginterferon Alfa-2a (Professional Patient Advice) - Drugs.com". www.drugs.com. from the original on 16 January 2017. Retrieved 12 January 2017.
  3. ^ "Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. from the original on 13 January 2017. Retrieved 12 January 2017.
  4. ^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 639. ISBN 9780857111562.
  5. ^ a b "Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. from the original on 23 December 2016. Retrieved 12 January 2017.
  6. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. ^ "Interferon alfa-2a Uses, Side Effects & Warnings". Drugs.com. Retrieved 10 January 2020.
  8. ^ Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
  9. ^ Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
  10. ^ Rajender Reddy K, Modi MW, Pedder S (June 2002). "Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C". Advanced Drug Delivery Reviews. 54 (4): 571–86. doi:10.1016/s0169-409x(02)00028-5. PMID 12052715.
  11. ^ . Genentech. Archived from the original on 8 January 2023. Retrieved 8 January 2023.
  12. ^ (PDF). www.roche.de (German). Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
  13. ^ (PDF). Roche (in German). Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
  14. ^ "pharma& portfolio". zr pharma& GmbH. Retrieved 4 December 2021.
  15. ^ (PDF). Roche. Archived from the original (PDF) on 24 November 2021. Retrieved 4 December 2021.
  16. ^ "Pegasys". Roche Australia. Retrieved 8 January 2023.
  17. ^ Reddy U, Krzystolik M (2006). "Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration". Cochrane Database Syst Rev. 1 (1): CD005138. doi:10.1002/14651858.CD005138.pub2. PMID 16437522.

External links edit

 
Wikimedia Commons has media related to Interferon-alpha 2a.

May 07, 2024
peginterferon, alfa, pegylated, interferon, alfa, sold, under, brand, name, pegasys, among, others, medication, used, treat, hepatitis, hepatitis, hepatitis, typically, used, together, with, ribavirin, cure, rates, between, hepatitis, used, alone, given, injec. Pegylated interferon alfa 2a sold under the brand name Pegasys among others is medication used to treat hepatitis C and hepatitis B 2 For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92 2 3 For hepatitis B it may be used alone 4 It is given by injection under the skin 2 Peginterferon alfa 2aClinical dataTrade namesPegasys othersAHFS Drugs comProfessional Drug FactsMedlinePlusa605029License dataUS DailyMed Peginterferon alfa 2aPregnancycategoryAU B3Routes ofadministrationSubcutaneous injectionATC codeL03AB11 WHO L03AB61 WHO in combinations Legal statusLegal statusAU S4 Prescription only UK POM Prescription only US WARNING 1 Rx only EU Rx only In general Prescription only IdentifiersCAS Number198153 51 4 Yalfa 2b 215647 85 1 YDrugBankDB00008 YChemSpidernoneUNIIQ46947ZFE7Kalfa 2b G8RGG88B68 YKEGGD02748 YChEMBLChEMBL1201560 NChemical and physical dataFormulaC 860H 1353N 227O 255S 9Molar mass19241 16 g mol 1 N Y what is this verify Side effects are common 5 They may include headache feeling tired depression trouble sleeping hair loss nausea pain at the site of injection and fever 2 Severe side effects may include psychosis autoimmune disorders blood clots or infections 2 Use with ribavirin is not recommended during pregnancy 2 Pegylated interferon alfa 2a is in the alpha interferon family of medications 2 It is pegylated to protect the molecule from breakdown 5 Pegylated interferon alfa 2a was approved for medical use in the United States in 2002 2 It is on the World Health Organization s List of Essential Medicines 6 Contents 1 Medical uses 1 1 Host genetic factors 2 Manufacturing 3 Society and culture 3 1 Availability 4 Research 5 References 6 External linksMedical uses editThis drug is approved around the world for the treatment of chronic hepatitis C including people with HIV co infection cirrhosis normal levels of ALT and has recently been approved in the EU U S China and many other countries for the treatment of chronic hepatitis B It is also used in the treatment of certain T cell lymphomas particularly mycosis fungoides citation needed Peginterferon alfa 2a is a long acting interferon Interferons are proteins released in the body in response to viral infections Interferons are important for fighting viruses in the body for regulating reproduction of cells and for regulating the immune system 7 Host genetic factors edit For genotype 1 hepatitis C treated with pegylated interferon alfa 2a or pegylated interferon alfa 2b combined with ribavirin it has been shown that genetic polymorphisms near the human IL28B gene encoding interferon lambda 3 are associated with significant differences in response to the treatment This finding originally reported in Nature 8 showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others Another report in Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus 9 Manufacturing editIt is pegylated with a branched 40 kg mol PEG chain 10 Society and culture editAvailability edit Peginterferon alfa 2a is manufactured under the brand name Pegasys In 2021 Roche Pharmaceuticals sold the worldwide rights of Pegasys excluding China and Japan to zr pharma amp GmbH pharma amp 11 12 13 14 15 In May 2022 Roche Australia transferred the sales and marketing of Pegasys to Echo Therapeutics Pty Ltd 16 Research editA Cochrane Review sought to determine whether interferon alfa 2a could be used as a treatment for individuals with neovascular age related macular degeneration They found no evidence of improved visual acuity with potential harm 17 References edit FDA sourced list of all drugs with black box warnings Use Download Full Results and View Query links nctr crs fda gov FDA Retrieved 22 October 2023 a b c d e f g h Peginterferon Alfa 2a Professional Patient Advice Drugs com www drugs com Archived from the original on 16 January 2017 Retrieved 12 January 2017 Pegasys 135 mcg and 180 mcg solution for injection in pre filled pen Summary of Product Characteristics SPC eMC www medicines org uk Archived from the original on 13 January 2017 Retrieved 12 January 2017 British national formulary BNF 69 69 ed British Medical Association 2015 p 639 ISBN 9780857111562 a b Peginterferon alfa 2a Pegasys Treatment Hepatitis C Online www hepatitisc uw edu Archived from the original on 23 December 2016 Retrieved 12 January 2017 World Health Organization 2019 World Health Organization model list of essential medicines 21st list 2019 Geneva World Health Organization hdl 10665 325771 WHO MVP EMP IAU 2019 06 License CC BY NC SA 3 0 IGO Interferon alfa 2a Uses Side Effects amp Warnings Drugs com Retrieved 10 January 2020 Ge D Fellay J Thompson AJ et al 2009 Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance Nature 461 7262 399 401 Bibcode 2009Natur 461 399G doi 10 1038 nature08309 PMID 19684573 S2CID 1707096 Thomas DL Thio CL Martin MP et al 2009 Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 798 801 Bibcode 2009Natur 461 798T doi 10 1038 nature08463 PMC 3172006 PMID 19759533 Rajender Reddy K Modi MW Pedder S June 2002 Use of peginterferon alfa 2a 40 KD Pegasys for the treatment of hepatitis C Advanced Drug Delivery Reviews 54 4 571 86 doi 10 1016 s0169 409x 02 00028 5 PMID 12052715 Pegasys peginterferon alfa 2a Genentech Archived from the original on 8 January 2023 Retrieved 8 January 2023 Verzichtserklarung der Zulassung Mittelfristig lauft Pegasys aus PDF www roche de German Archived from the original PDF on 4 December 2021 Retrieved 4 December 2021 Pegasys Peginterferon alfa 2a langfristig weiterhin erhaltlich PDF Roche in German Archived from the original PDF on 4 December 2021 Retrieved 4 December 2021 pharma amp portfolio zr pharma amp GmbH Retrieved 4 December 2021 HALF YEAR REPORT 2021 p 20 PDF Roche Archived from the original PDF on 24 November 2021 Retrieved 4 December 2021 Pegasys Roche Australia Retrieved 8 January 2023 Reddy U Krzystolik M 2006 Antiangiogenic therapy with interferon alfa for neovascular age related macular degeneration Cochrane Database Syst Rev 1 1 CD005138 doi 10 1002 14651858 CD005138 pub2 PMID 16437522 External links edit nbsp Wikimedia Commons has media related to Interferon alpha 2a Pegasys at the U S National Library of Medicine Medical Subject Headings MeSH Portals nbsp Medicine nbsp Viruses Retrieved from https en wikipedia org w index php title Peginterferon alfa 2a amp oldid 1214240864, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.